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ABSTRACT 
 
Numerous studies have indicated that dysregulation of the 
immune system occurs during or after spaceflight. Using 
21 day 6º head-down tilt bed rest as a spaceflight analog, 
this study describes the effects of a daily artificial gravity 
(AG) countermeasure treatment on immunity, stress, and 
reactivation of clinically important latent herpes viruses. 
Blood, saliva, and urine samples were collected from each 
of the 15 male test subjects (8 treatment, 7 control) 
periodically throughout the study. The immune 
assessment consisted of a comprehensive peripheral 
immunophenotype analysis, intracellular cytokine 
profiles, and measurement of T cell function. With the 
exception of mild reactivation of Epstein-Barr (EBV) and 
Varicella zoster (VZV) viruses, no significant changes in 
immune function were observed, suggesting that the AG 
countermeasure and the 21 day head-down tilt bed rest 
regimen had no adverse effect on immune function.  
 
 
1. INTRODUCTION 
 
Space flight is a unique experience and results in adverse 
effects on human physiology. Changes have been 
reported in the musculoskeletal, neurovestibular, 
cardiovascular, endocrine, and immune systems as well as 
others [1]. As NASA goes forward, preparing for longer 
exploration missions to the Moon, Mars, and eventually 
beyond, effective countermeasures to these adverse 
effects on humans must be developed, verified, and 
implemented to ensure mission success. Many of the 
significant adverse effects of space flight on human 
physiology are caused by various stressors. These include 
isolation, confinement, anxiety, sleep deprivation, 
psychosocial interactions, and physical exertion. The 
physical environment further subjects the crew to noise, 
chemical and microbiological contaminants, increased 
radiation, and variable gravity forces (hyper- and hypo-
gravity). Many of these stress factors are intermittent, but 
some are relatively constant (such as microgravity on 
long missions).  
 
Research on astronaut physiology in space is complicated 
by exposure to these and other uncontrolled factors. 
Research is further slowed by the limited access to space 
and availability of microgravity-compatible technology 
for on-board analyses. For these reasons, high-fidelity 
ground-based analogs of space flight are essential tools 
for studying the effects of space flight on human 
physiology, developing countermeasures as needed, and 
testing the efficacy of countermeasures.  
 
Various ground-based analogs have been developed and 
used to model specific aspects of space flight. Bed rest 
has been successfully used to model the effects of 
microgravity on musculoskeletal and some other 
physiological systems. The immune system is affected by 
space flight, and some analogs have been used to study 
various aspects of immunity at the cellular level. Some 
success in studying the effects of space flight on the 
immune system has also been achieved in specific animal 
models [2,3]. Stress models such as Antarctic science 
stations and others have been useful in study of the effect 
of stress on human immunity [4]. Generally, human bed 
rest has not been demonstrated to be a highly useful 
model for human immunity studies. However, the use of 
artificial gravity (AG) as a countermeasure for some other 
physiological systems (e.g., musculoskeletal) may impact 
some elements of immunity. The immune system 
interacts with most if not all other physiological systems. 
From this perspective, measuring selected indicators of 
immune status makes a valuable contribution to the 
overall study of efficacy of AG as a countermeasure for 
other physiological systems. In the current study, we 
tested the combined effects of hypergravity and stress and 
other factors associated with bed rest on changes in 
immunity and reactivation of latent herpes viruses.  
 
 
2. METHODS 
 
Fifteen human subjects completed the study. All subjects 
spent 41 days residing in the NIH-supported General 
Clinical Research Center (GCRC) located at the 
University of Texas Medical Branch (UTMB) in 
Galveston, TX and were deconditioned by 6o head-down 
tilt bed rest for 21 of those days. Subjects in the 
Treatment group (n=8) received one hour of AG via 
centrifugation daily. Subjects in the Control group (n=7) 
did not receive any countermeasure. All human study 
protocols were approved by the Committee for the 
https://ntrs.nasa.gov/search.jsp?R=20070013697 2019-08-30T00:33:46+00:00Z
Protection of Human Subjects at the Johnson Space 
Center, Houston, TX, and the Institutional Review Board 
at UTMB; informed consent was obtained from all 
subjects.  
 
Blood, saliva, and urine samples were collected from each 
participating subject in this study according to the 
schedule shown in Fig. 1. Simultaneously, psychological 
stress was measured in each subject at the time of saliva 
collection using a questionnaire (Fig. 1). Blood samples 
were used to measure concentrations of stress hormones 
and titers of antibodies to viruses and to conduct tests of 
immune system status, including measurement of virus-
specific T-cell number and function. Shedding of viral 
DNA was quantified in saliva and urine samples, and 
urine samples were used to measure excretion of stress 
hormones. 
 
 
 
 
 
 
 
 
 
Fig. 1. Schedule for blood, saliva, and urine collection. 
 
2.1 Psychological Stress 
Psychological stress was measured by asking each 
participating subject to complete two questionnaires, the 
Perceived Stress Scale (PSS) and the Positive Affect and 
Negative Affect Scale (PANAS). These questionnaires 
were completed first thing in the morning, on days before, 
during, and after the subjects’ saliva was collected. The 
questionnaires were scored and data were analyzed 
statistically.  
 
The 10-item PSS [5] was used to measure the extent to 
which participants perceived their recent life 
circumstances as stressful (that is, unpredictable, 
uncontrollable, and overloading). Participants rate each of 
the 10 statements on a 5-point scale (0 = never to 4 = very 
often), so that scores range from 0 to 40. The scale is 
internally consistent and has demonstrated moderate 
correlations with other measures of appraised stress [6]. 
 
2.2 Physiological Stress  
Plasma and salivary cortisol measurements were done by 
methods previously described [7]. 
 
2.3 Immune System Status 
 
2.3.1 Immunophenotype analysis 
A moderate four-color flow cytometry antibody matrix 
was created to assess all the major leukocyte/lymphocyte 
subsets, as well as activated and memory/naïve T cell 
subsets. Cell surface markers were stained first combining 
100 μl of EDTA whole blood and 10 μg of each 
appropriate labeled monoclonal antibodies. Staining was 
performed by incubated at room temperature for 20 
minutes. Red blood cells were lysed using Beckman-
Coulter optilyse as described by the manufacturer. 
Stained leukocytes were then fixed in 1.0% 
paraformaldehyde in PBS for 10 minutes and analyzed on 
a Beckman-Coulter Epics XL flow cytometer. The 
cytometry panel is outlined in Table 1. The white blood 
cell count (WBC) and differential were performed at the 
indicated time points using a Beckman-Coulter 
Hematology Analyzer.  
 
Table 1. Flow cytometry panel for Bed Rest Campaigns. 
FL FL FL FL CELL TYPES 
CD1 CD1 CD4 WBC 
CD CD1 CD1 CD4 T cells, NK 
CD CD CD T cell 
CD45R CD45R CD CD Memory/naïve T cell 
HLA- CD6 CD CD Early-, late-activated T cell  
 
2.3.2 Intracellular cytokine analysis   
Lymphocyte and monocyte cytokine production were 
assessed for specific cell subsets at the single-cell level 
utilizing intracellular flow cytometry. The unique 
advantage of intracellular flow cytometry is the ability to 
assess the production of multiple cytokines 
simultaneously in positively identified cell sub-
populations using multi-color flow cytometry. Whole 
blood cultures were set up by adding 100 μl heparin 
whole blood to 1.0 culture media containing 10 ng/ml 
PMA, 1.0 μg/ml ionomycin and 3 μM monensin. Cultures 
were incubated for 4.0 hours at 37o C. Following 
incubation, the supernatants were removed, the RBCs 
lysed as noted above, and the remaining WBCs were 
fixed in 4.0% paraformaldehyde for 10 minutes. To detect 
intracellular production of IFNγ or IL-2 (following 
surface marker staining), the fixed PBMC's were 
resuspended in 200 μl of permeabilization buffer, 
consisting of 5.0% non-fat dry milk and 0.5% saponin in 
PBS to which 0.5 μg of labeled mouse antibody to either 
IFNγ or IL-2 (or both) was added. The cells were 
incubated at room temperature for 25 minutes and then 
washed in PBS containing saponin. The cells were then 
resuspended in 1.0% paraformaldehyde for analysis.  
 
2.3.3 T cell function 
Immune suppression may consist of a reduced capacity 
for lymphocytes to respond to stimulus, even though the 
relative distribution of immune cells is unchanged. For 
this study the functional response of T cells was measured 
by activating whole blood cultures in the presence of T 
cell mitogenic stimuli, followed by measurement of 
surface activation marker expression on T cell subsets. 
Culture in the presence of anti-CD3 and anti-CD28 
antibodies was used for T cell stimulation. These 
antibodies activate T cells by triggering T cell surface 
molecules, requiring the full compliment of intracellular 
signaling to be utilized (as opposed to phorbol ester or 
ionomycin). T cell progression through a full activation 
cycle may be monitored by culturing cells for 24 hours 
and determining the expression of cell surface CD69 
(early activation), CD25 (mid-activation, receptor for IL-
2 that requires new gene synthesis).  
 
2.3.4 Tetramer assay 
HLA-A*0201-restricted tetramers (EBV BMLF; CMV 
pp65) were obtained from Beckman Coulter (San Diego, 
CA). PBMCs were incubated with PE- or APC-labeled 
MHC-tetramer complexes, along with CD8-PerCP (BD 
Biosciences), in dPBS with 2% FCS for 30 minutes at 
room temperature. Cells were then washed and fixed in 
1% PFA and analyzed on a FACSCalibur flow cytometer 
using CellQuest software for data collection and analysis.  
 
2.3.5 Peptide stimulation assay   
Intracellular cytokine staining assays were performed as 
described elsewhere [8,9]. PBMCs were isolated from 
heparinized whole blood by density-gradient 
centrifugation and washed three times in Dulbecco’s 
phosphate-buffered saline (dPBS) prior to use in 
functional studies. PBMCs were used immediately and 
stimulated with HLA-A*0201-restricted epitopic peptides 
(10 ug/ml/peptide), controls (PBS) or staphylococcus 
enterotoxin B (SEB) (10 ug/mL). Peptides used in this 
study were CMV pp65 (residues 495-503; 
NLVPMVATV) and EBV BMLF (residues 280-288; 
GLCTLVAML). Costimulatory monoclonal antibodies 
(mAbs) – CD28 and CD49d mAbs (1 ug/ml each) (BD 
Immunocytometry Systems) – were added to each tube. 
The tubes were vortexed and incubated for 6 h at 37ºC 
with 5% CO2, with the addition of Brefeldin A (10 ug/ml; 
Sigma) for the last 5 h. Following stimulation, cells were 
washed in PBS, incubated for 5 min at 37ºC in 0.02% 
EDTA and washed in dPBS. Cells were then sequentially 
incubated for 10 minutes in FACSLyse and FACSPerm 
solutions (both from Becton-Dickinson Biosciences), 
washed, and stained with anti-IFN-γ (PE), anti-TNF-a 
(FITC), anti-CD8 (PerCP), and anti-CD69 (APC) 
antibodies. Samples were then fixed in 1% 
paraformaldehyde and analyzed by four-color flow 
cytometry using a FACSCalibur cytometer and CellQuest 
software (both BD Biosciences).  
 
2.4 Viral Reactivation Assessment 
 
2.4.1 Viral DNA by polymerase chain reaction   
PCR was performed on either urine, saliva, or 1x106 
peripheral blood mononuclear cells. 3.0 ml of each urine 
sample or 2.0 ml of saliva was concentrated to ~200 uL 
by centrifugation using a Microsep concentrator 100K 
(Pall Filtron Corp., Northborough, MA). Extraction of 
genomic/viral DNA from concentrated urine was 
performed using the QIAamp Viral RNA Kit (Qiagen 
Inc., Santa Clarita, CA) according to the manufacturer’s 
instructions. EBV and VZV DNA were quantitated by 
real-time PCR using an ABI 7700 sequence detector 
[10,11,12]. CMV DNA was quantitated using the same 
methodology but with primers that targeted the immediate 
early gene [13].  
 
2.4.2 Plasma viral antibody levels   
Anti-viral antibody titers were determined by indirect 
immunofluorescence as previously described [7,12,14]. 
Commercially prepared substrate slides and control sera 
(Bion Enterprises, Park Ridge, IL) were used for 
determining IgG antibody titers to EBV-viral capsid 
antigen (VCA) and early antigen (EA), EBV-nuclear 
antigen (EBNA), VZV and CMV. Two-fold dilutions of 
plasma or serum from each subject were prepared, and the 
endpoint titer was determined as the highest dilution of 
serum still able to demonstrate immunofluorescence-
positive cells. All specimens were batch analyzed and 
read blind-coded.  
 
3. RESULTS 
 
3.1 Psychological and Physiological stress  
 
3.1.1 PSS and PANAS results 
A total of 318 behavioral measurements for PSS and 
PANAS scores were collected from all 15 subjects during 
the 41 day study. No significant differences were found in 
PANAS or PSS during 21-day bed rest period (compared 
to the pre-bed rest values) nor were any differences found 
between the control and treatment groups.  
 
3.1.2 Cortisol levels 
Salivary cortisol levels were measured in all subjects. No 
significant changes were observed between the treatment 
or control subjects or between the time intervals before, 
during or after the 21 day bed rest. Likewise with plasma 
cortisol levels, no significant differences were found 
either between or within the treatment or control groups.  
 
3.2 Immune assessment 
The peripheral immunophenotype was assessed for all 
subjects and consisted of a leukocyte differential, 
lymphocyte subsets, and the following T cell subsets: 
CD4/CD8 ratio, memory/naïve (CD45RA+/-), early 
activated (CD69+) and late activated (HLA-DR+). The 
control subjects displayed an elevated percentage of 
granulocytes that persisted over the duration of the head-
down phase and resolved by R+9, that was not observed 
in the treatment subjects. This change was not statistically 
significant. In general, no other consistent differences 
were observed in the peripheral leukocyte distribution for 
any of the subsets measured for either the treatment or 
control subjects. Intracellular IFNγ and IL-2 were 
assessed for both the CD4+ and CD8+ T cell subsets 
following 5 hours stimulation with PMA+ionomycin. The 
treatment subjects displayed a significant decrease in the 
CD4+/IFNγ+ subset and a non-significant trend towards 
05
10
15
20D
4
25
30
35
L-9 BR+7 BR+14 R+0 R+9
Pe
rc
en
ta
ge
 (C
/IF
N
g)
   
 
Control
Treatment
 *Number of samples 
positive for  VZV 
*Number of samples 
positive for  CMV 
 Treatment Control Treatment Control 
Before 1/44 3/35 1/18 1/16 
During 1/92 4/67 1/30 3/24 
After 1/40 1/40 0/18 1/13 
 
EBV copies Frequency 
Treatment Control Treatment Control
  
  Mean SD Mean SD % % 
 
Four of the treatment subjects were HLA-A2 positive, 
while only one of the control subjects was positive. This 
limited data analysis for the MHC tetramers and peptide-
stimulation assays. However, no differences were found 
in the levels of either CMV or EBV-specific CD8+ T-
cells as revealed by MHC tetramer staining nor functional 
differences as determined by intracellular cytokine 
synthesis (IFN-γ and TNF-α) following viral-peptide 
stimulation. 
reduced CD8+/IFNγ+  at BR+7 as compared to baseline 
values (Fig. 2). This change was not evident in the control 
subjects. In fact, the control subjects demonstrated an 
increase in CD4+/IFNγ percentage that was not 
significant. No changes were observed for the CD4+/IL-2 
and CD8+/IL-2 subsets. T cell function was assessed by 
stimulating T cells with soluble CD3/CD28 antibodies for 
24 hours and measuring the percentage of responding 
CD69+/CD25+ T cell subsets. There appeared to be no 
observable alterations in T cell function for either the 
treatment or the control subjects.  
 
Before 17.2 32.1 29.6 80.6 21.4 20.0 
During 43.8 88.4 79.7 145.7 22.8 32.1 
After 40.1 45.8 58.7 38.8 18.0 24.2 
 
 
 
 
 
                                           *                                     
 
 
 
 
 
 
 
 
Fig. 2. CD4/IFNγ Profiles. 
 
3.3 Viral Reactivation 
 
Antibody titers to EBV-VCA, -EA, EBNA, and CMV 
were measured in the control and treatment groups over 
the course of the study. No significant changes were 
found in any of the antiviral IgG antibodies between or 
within the groups.  
 
Salivary EBV was detected frequently in both control 
group and treatment group. However, its frequency and 
copy number did not change significantly between the 
groups or before, during, and after bed rest. The 
frequency of VZV DNA was found in fewer of the saliva 
samples collected from treatment subjects than the 
samples from control. Similarly, CMV was also found 
less frequently in samples collected from treatment 
subjects as compared to the control subjects (Table 2). 
EBV DNA levels in peripheral blood PBMCs were also 
measured. The levels of EBV DNA were generally 
undectable and never exceeded 1,500 copies per 106 
PBMCs; no differences were found between the groups.  
 
Table 2. Viral shedding in 15 subjects before, during and 
after a 21 day AG study. 
 
a)  EBV (frequency of EBV shedding in 14 healthy adults 
was 3.4%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) VZV (VZV copies as measured by real time PCR were 
between 23 and 43/ml saliva) and CMV (frequency of 
CMV shedding in 14 healthy adults was less than 1.6%) 
 
 
 
 
 
 
 
 
 
 
 
 
4. DISCUSSION 
 
As peripheral phenotypic changes are generally 
associated with subject pathology, it was not unexpected 
that there were essentially no peripheral phenotype 
alterations in any of the subjects. This is consistent with 
healthy individuals who are essentially ‘isolated’ from 
society for a period of time. We did not expect them to 
become ‘ill’. However, data from spaceflight and other 
ground-based spaceflight analogs has indicated that 
immune functional changes can be expected from healthy 
individuals experiencing unexpected, potentially stressful 
conditions like spaceflight. The reduced percentage of 
IFNγ producing T cell subsets observed at BR+7 in the 
treatment group, but not the control group (Fig. 2), may 
be an initial stress response to daily centrifugation. The 
fact that this alteration corrects itself by BR+14 lends 
support to this idea. There were no observed changes in 
the T cell function assessments for either treatment or 
control subjects. These data indicate that there was there 
no observable immune-related pathology during the bed 
rest phase for either subject group. In addition, there was 
no other adverse effect on generalized immune function. 
Thus, neither the 21 day bed rest nor the daily AG 
treatment appeared to adversely affect immunity. 
 
We have previously reported increase viral (EBV, VZV 
and CMV) reactivation during space flight as well as 
ground-based space analog studies [15]. In this study, 
though there was an increasing trend in the EBV 
reactivation during the 21 day bed rest period in the 
subjects in both groups (EBV frequency 21%), these 
increases were not significantly different. It is interesting 
to note that VZV and CMV which are not shed in normal 
healthy subjects, showed a slight decrease in the subjects 
who had undergone AG treatment as compared to the 
control group suggesting that AG may help in lowering 
the CMV and VZV shedding in these subjects.  
 
In summary, our data suggest that stress associated with 
21 days of bed rest along with artificial gravity 
countermeasure did not have a major affect on the 
behavioral assessment scores, salivary cortisol and 
reactivation of EBV, CMV and VZV. 
 
(Supported by NASA HRP; conducted at the NIH-funded 
[M01 RR 0073] GCRC at UTMB, Galveston, TX) 
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